CRIS and ARQL are like looking in a mirror , just a few months apart.
19 different trials for GDC-0449 (NCT01088815 with Abraxis); 2 phase data to be release 2nd half, one may be at ASCO by Roche.
Multi-target Kinase inhibitor program.
101 hits 5 targets with a single agent
906 hits 7 targets with a single agent
This is a trick question, see if you can spot which object does not belong (or may be it does!)?
EXEL as of yesterday morning. It looks very oversold to me. Should at least make a run back to 7 in the coming weeks. Could run a bit higher in anticipation of ASCO. They have 12 posters at the event. ARQL is still by far my favorite right now though. I think it is an easy double in the coming weeks.